NASDAQ:ALLR Allarity Therapeutics Earnings Date & Estimates $0.92 -0.02 (-2.45%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Allarity Therapeutics is estimated to report earnings on Friday, November 13, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 13, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Allarity TherapeuticsAllarity Therapeutics is expected to post earnings of -$0.21 per share. In the same quarter a year earlier Allarity Therapeutics reported -$0.19 per share. Allarity Therapeutics last reported on August 14, 2026, posting -$0.21 per share and beating the -$0.25 consensus estimate. Allarity Therapeutics has beaten the consensus EPS estimate in 6 of its last 6 quarters.Consensus EstimatesConsensus EPS-$0.21Prior-Year EPS-$0.19Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.21 (Beat by +$0.04)EPS Beat Rate6 of last 6 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Allarity Therapeutics Earnings FAQ When does Allarity Therapeutics report earnings? Allarity Therapeutics (NASDAQ:ALLR) is estimated to report earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Allarity Therapeutics? Analysts expect Allarity Therapeutics to post earnings of -$0.21 per share for the quarter. Allarity Therapeutics Earnings HeadlinesAllarity Therapeutics (ALLR) Expected to Post Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comAllarity Therapeutics Signs First Revenue-Generating CLIA Services Deal; Stock DownOctober 31, 2026 | rttnews.comMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.November 10 at 1:00 AM | Porter & Company (Ad)Allarity Therapeutics Ends Stock Purchase Agreement, Shifts FinancingOctober 30, 2026 | tipranks.comAllarity Therapeutics Announces First Commercial CLIA Laboratory Services AgreementOctober 30, 2026 | quiverquant.comQAllarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring RevenueOctober 30, 2026 | globenewswire.comSee More Allarity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Allarity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allarity Therapeutics and other key companies, straight to your email. Email Address About Allarity TherapeuticsAllarity Therapeutics (NASDAQ:ALLR) (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology. The company has also evaluated other targeted cancer therapies and drug combinations through its precision-medicine platform. Allarity does not have commercially approved products and remains focused on clinical development and regulatory activities. The company originated in Denmark under the name Oncology Venture and adopted the Allarity Therapeutics name in 2021. Its operations and research activities have been associated with Denmark and the United States, while its investigational programs have been intended for international clinical development. Information about current leadership and active development programs may change as the company’s clinical and corporate plans evolve.View Allarity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
